{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:08:25Z","timestamp":1790813305215,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>In the past decade, the treatment methods for small-cell lung cancer (SCLC) have undergone advances and diversification. This study aimed to explore the treatment patterns of patients with SCLC and evaluate the efficacy of SCLC treatments in a real clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This retrospective study included patients with limited-stage (LS) and extensive-stage (ES) SCLC who received treatment at Qingdao Central Hospital (Qingdao, China) from August 1, 2016, to April 30, 2023. The progression-free survival (PFS) and overall survival (OS) were evaluated for all enrolled patients and participant subgroups via Kaplan\u2013Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 83 and 117 patients with LS-SCLC and ES-SCLC, respectively, were enrolled. The median PFS and OS were 14.5 and 33.4 months for the LS-SCLC group and 9.8 and 20.1 months for the ES-SCLC group, respectively. First-line thoracic consolidative radiotherapy (TRT) and immune checkpoint inhibitors markedly prolonged the PFS in the ES-SCLC group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .023 and P = .045, respectively), whereas TRT alone significantly prolonged the OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .036). PFS and OS were significantly prolonged in the LS-SCLC group in whom TRT was initiated during or before the second cycle of first-line chemotherapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .031 and P = .041, respectively). Moreover, patients with at least three areas of lymph node metastasis had significantly poorer prognosis than those with fewer areas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The patients in this study exhibited better prognosis than those in previous ones. TRT remains an important treatment that can improve the prognosis of patients with SCLC. However, new strategies are warranted for a more effective treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_251_25","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:04:08Z","timestamp":1756998248000},"page":"924-933","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Precision treatment patterns and prognostic analysis: A retrospective study of small-cell lung cancer"],"prefix":"10.4103","volume":"21","author":[{"given":"Yiming","family":"Wang","sequence":"first","affiliation":[{"name":"Qingdao Medical College, Qingdao University, Qingdao, China"},{"name":"Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"R1-20250905","doi-asserted-by":"crossref","first-page":"210079","DOI":"10.1183\/16000617.0079-2021","article-title":"Recent developments in the treatment of small cell lung cancer","volume":"30","author":"Hiddinga","year":"2021","journal-title":"Eur Respir Rev"},{"key":"R2-20250905","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20250905","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.hoc.2016.08.005","article-title":"Advances in small cell lung cancer","volume":"31","author":"Kalemkerian","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"R4-20250905","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R5-20250905","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: Where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"R6-20250905","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20250905","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2013.0011","article-title":"Small cell lung cancer","volume":"11","author":"Kalemkerian","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20250905","first-page":"26","article-title":"Treatment for small cell lung cancer, where are we now?- A review","volume":"5","author":"Alvarado-Luna","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R9-20250905","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"R10-20250905","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1993.11.2.336","article-title":"Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The national cancer institute of Canada clinical trials group","volume":"11","author":"Murray","year":"1993","journal-title":"J Clin Oncol"},{"key":"R11-20250905","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2017.06.002","article-title":"Treatment advances in small cell lung cancer (SCLC)","volume":"180","author":"Waqar","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R12-20250905","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1002\/cncr.26206","article-title":"Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"R13-20250905","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"R14-20250905","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cllc.2015.09.007","article-title":"Thoracic radiotherapy for extensive stage small-cell lung cancer: A meta-analysis","volume":"17","author":"Palma","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R15-20250905","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R16-20250905","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R17-20250905","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R18-20250905","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R19-20250905","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijc.28015","article-title":"Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer","volume":"133","author":"Vermeer","year":"2013","journal-title":"Int J Cancer"},{"key":"R20-20250905","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Med"},{"key":"R21-20250905","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.21037\/jtd-20-3034","article-title":"Real-world treatment patterns and outcomes in small-cell lung cancer: A systematic literature review","volume":"13","author":"Johal","year":"2021","journal-title":"J Thorac Dis"},{"key":"R22-20250905","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/1759-7714.14289","article-title":"Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period","volume":"13","author":"Ni","year":"2022","journal-title":"Thorac Cancer"},{"key":"R23-20250905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2021.11.013","article-title":"FRESC: French real world extensive stage SCLC cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010","volume":"164","author":"Debieuvre","year":"2022","journal-title":"Lung Cancer"},{"key":"R24-20250905","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cllc.2018.12.019","article-title":"Advancements in small-cell lung cancer: The changing landscape following IMpower-133","volume":"20","author":"Pacheco","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R25-20250905","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17476348.2020.1681977","article-title":"Nivolumab for the treatment of small cell lung cancer","volume":"14","author":"Simeone","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"R26-20250905","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.7150\/jca.13080","article-title":"Second-line therapy of small-cell lung cancer: Topotecan compared to a combination treatment with Adriamycin, cyclophosphamide and vincristine (ACO) - A single center experience","volume":"6","author":"Hagmann","year":"2015","journal-title":"J Cancer"},{"key":"R27-20250905","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000486038","article-title":"Efficacy of platinum-based chemotherapy for relapsed small-cell lung cancer after amrubicin monotherapy in elderly patients and patients with poor performance status","volume":"94","author":"Igawa","year":"2018","journal-title":"Oncology"},{"key":"R28-20250905","first-page":"161","article-title":"Feasibility and long-term outcomes of post-chemotherapy-based consolidation radiotherapy in extensive stage small-cell lung cancer","volume":"3","author":"Jie","year":"2023","journal-title":"J Natl Cancer Cent"},{"key":"R29-20250905","first-page":"139","article-title":"Radiotherapy may improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study","volume":"19","author":"Shang","year":"2020","journal-title":"Oncol Lett"},{"key":"R30-20250905","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/jcrt.jcrt_1015_24","article-title":"Evaluation of tumor control probability and normal tissue complication probability in IMRT and VMAT: A comparative study for assessment of efficacy of radiotherapy plans in tumors of the thorax","volume":"21","author":"Srivastava","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R31-20250905","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"R32-20250905","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"R33-20250905","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/1759-7714.15310","article-title":"Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Thorac Cancer"},{"key":"R34-20250905","doi-asserted-by":"crossref","first-page":"1197044","DOI":"10.3389\/fimmu.2023.1197044","article-title":"Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: A Bayesian network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"R35-20250905","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4103\/jcrt.jcrt_500_24","article-title":"Clinical features and prognosis analysis of stage III\/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective","volume":"20","author":"Wang","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R36-20250905","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4103\/jcrt.JCRT_1762_20","article-title":"Prognostic value of diffuse cancer inflammation index (ALI), serum neutrophil\/lymphocyte (NLR) and platelet\/lymphocyte (PLR) in advanced-stage lung cancer","volume":"20","author":"Ozturk","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R37-20250905","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.21037\/tlcr-23-294","article-title":"Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: A multicenter retrospective analysis","volume":"12","author":"Cai","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"R38-20250905","doi-asserted-by":"crossref","first-page":"102795","DOI":"10.1016\/j.eclinm.2024.102795","article-title":"Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): A phase II trial","volume":"75","author":"Chen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R39-20250905","doi-asserted-by":"crossref","first-page":"110014","DOI":"10.1016\/j.radonc.2023.110014","article-title":"Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis","volume":"190","author":"Feng","year":"2024","journal-title":"Radiother Oncol"},{"key":"R40-20250905","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0b013e3181b27799","article-title":"The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"4","author":"Valli\u00e8res","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_251_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:32:36Z","timestamp":1787837556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_251_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_251_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}